Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, Damasceno A, Avezum A, Dans AML, Gitura B, Hu D, Kamanzi ER, Maklady F, Fana G, Gonzalez-Hermosillo JA, Musuku J, Kazmi K, Zühlke L, Gondwe L, Ma C, Paniagua M, Ogah OS, Molefe-Baikai OJ, Lwabi P, Chillo P, Sharma SK, Cabral TTJ, Tarhuni WM, Benz A, van Eikels M, Krol A, Pattath D, Balasubramanian K, Rangarajan S, Ramasundarahettige C, Mayosi B, Yusuf S; INVICTUS Investigators. Connolly SJ, et al. N Engl J Med. 2022 Sep 15;387(11):978-988. doi: 10.1056/NEJMoa2209051. Epub 2022 Aug 28. N Engl J Med. 2022. PMID: 36036525 Clinical Trial.
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.
Karthikeyan G, Connolly SJ, Ntsekhe M, Benz A, Rangarajan S, Lewis G, Yun Y, Sharma SK, Maklady F, Elghamrawy AE, Kazmi K, Cabral TTJ, Dayi H, Changsheng M, Gitura BM, Avezum A, Zuhlke L, Lwabi P, Haileamlak A, Ogah O, Chillo P, Paniagua M, ElSayed A, Dans A, Gondwe-Chunda L, Molefe-Baikai OJ, Gonzalez-Hermosillo JA, Hakim J, Damasceno A, Kamanzi ER, Musuku J, Davletov K, Connolly K, Mayosi BM, Yusuf S; INVICTUS Investigators. Karthikeyan G, et al. Among authors: dayi h. Am Heart J. 2020 Jul;225:69-77. doi: 10.1016/j.ahj.2020.03.018. Epub 2020 Mar 25. Am Heart J. 2020. PMID: 32474206
Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two 'missed doses': a randomised, double-blind comparative trial in Asian patients.
Ongtengco I, Morales D, Sanderson J, Lu ZR, Beilin LJ, Burke V, Puddey IB, Tanomsup S, Dayi H, Rahardjo P, Zambahari DR, Chen CY, Soenarta AA, Buranakitjaroen P, Tan C, Soon TK, Wu DJ. Ongtengco I, et al. Among authors: dayi h. J Hum Hypertens. 2002 Nov;16(11):805-13. doi: 10.1038/sj.jhh.1001485. J Hum Hypertens. 2002. PMID: 12444542 Clinical Trial.
Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
Bi Y, Gao R, Patel A, Su S, Gao W, Hu D, Huang D, Kong L, Qi W, Wu Y, Yang Y, Turnbull F; CPACS Investigators. Bi Y, et al. Am Heart J. 2009 Mar;157(3):509-516.e1. doi: 10.1016/j.ahj.2008.09.026. Epub 2008 Dec 17. Am Heart J. 2009. PMID: 19249422